Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200-Day Moving Average – What’s Next?

Predictive Oncology Inc. (NASDAQ:POAI) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $9.19 and traded as low as $2.34. Predictive Oncology shares last traded at $2.58, with a volume of 46,805 shares.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Predictive Oncology to a “strong sell” rating in a report on Saturday, December 6th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Predictive Oncology Price Performance

The company has a market cap of $8.28 million, a price-to-earnings ratio of -0.18 and a beta of 1.35. The firm has a fifty day simple moving average of $5.39 and a 200 day simple moving average of $9.13.

Predictive Oncology (NASDAQ:POAI) last issued its quarterly earnings data on Friday, November 14th. The medical instruments supplier reported ($4.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($3.17). Predictive Oncology had a negative return on equity of 732.73% and a negative net margin of 5,065.23%.The firm had revenue of $0.00 million during the quarter, compared to analyst estimates of $1.50 million. Analysts expect that Predictive Oncology Inc. will post -2.08 earnings per share for the current year.

Predictive Oncology Company Profile

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.